{
    "clinical_study": {
        "@rank": "120826", 
        "arm_group": [
            {
                "arm_group_label": "Group A", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "Group B", 
                "arm_group_type": "Active Comparator"
            }
        ], 
        "brief_summary": {
            "textblock": "The objective of this study is to compare pharmacokinetics after single oral administration\n      of 2 capsules of YH14659, a fixed-dose combination of clopidogrel and aspirin developed by\n      Yuhan Corporation versus co-administration of Plavix (clopidogrel) and Astrix (aspirin) in\n      healthy male volunteers."
        }, 
        "brief_title": "Comparative Pharmacokinetics of YH14659 in Healthy Male Subjects", 
        "completion_date": {
            "#text": "April 2012", 
            "@type": "Actual"
        }, 
        "condition": "Acute Coronary Syndrome", 
        "condition_browse": {
            "mesh_term": "Acute Coronary Syndrome"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Healthy male volunteers of aged between 20 years to 55 years\n\n          -  Weight: over 50kg, within \u00b120% of ideal body weight\n\n          -  Have no history of neither congenital nor chronic disease\n\n          -  Have no history of abnormal symptoms or opinions as a result of physical examination\n             (medical checkup)\n\n          -  Eligible subjects with acceptable medical history, physical examination, laboratory\n             tests, ECG during screening period\n\n          -  Subject who has signed on the written consent\n\n        Exclusion Criteria:\n\n          -  Have a known allergy or hypersensitivity to anti-platelet agents\n\n          -  Person with hypotension (SBP \u2264 100mmHg or DBP \u2264 50mmHg) or hypertension (SBP \u2265\n             150mmHg or DBP \u2265 95mmHg), person whose pulse rate is below 45 or over 100 a minute\n\n          -  Have the following abnormal findings on diagnosis;\n\n               -  have AST or ALT > 1.25 times of normal upper limit\n\n               -  have total bilirubin > 1.5 times of normal upper limit\n\n               -  have higher PT, aPPT, BT than normal range\n\n               -  have PLT below 180,000 or above 350,000\n\n          -  Patients with hemorrhage or predisposition to hemorrhage\n\n          -  Have disease or history of stomach or intestinal surgery or resection that would\n             potentially alter absorption of orally administered drugs\n\n          -  Have participated in other clinical studies within 3 months prior to the first\n             administration\n\n          -  Have used any prescription medications including anti-coagulants, anti-platelet\n             agents, thrombolytic drugs and Prostaglandin E1 agents within 2 weeks prior to the\n             first administration or any over-the-counter, non-prescription preparations within 1\n             week prior to the first administration\n\n          -  Patients with aspirin induced asthma(AIA) or history of AIA\n\n          -  Subject who is judged to be ineligible by principal investigator or sub-investigator"
            }, 
            "gender": "Male", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "55 Years", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "60", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "March 21, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01657071", 
            "org_study_id": "YH14659-102"
        }, 
        "intervention": [
            {
                "arm_group_label": "Group A", 
                "description": "YH14659 capsule by oral", 
                "intervention_name": "YH14659", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Group B", 
                "description": "clopidogrel tablet(75mg) + aspirin capsules(100mg) by oral", 
                "intervention_name": "clopidogrel & aspirin", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Aspirin", 
                "Clopidogrel"
            ]
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "August 2, 2012", 
        "location": {
            "facility": {
                "address": {
                    "city": "Seoul", 
                    "country": "Korea, Republic of", 
                    "zip": "156-754"
                }, 
                "name": "Yuhan Corporation"
            }
        }, 
        "location_countries": {
            "country": "Korea, Republic of"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Randomized, Open-label, Single Dose, 2-treatment, 2-period, 2-way Crossover Study to Assess the Pharmacokinetic Characteristics of YH14659, a Fixed Dose Combination Compared With Coadministration of Separate Constituents Under Fasted Conditions in Healthy Male Subjects", 
        "overall_official": {
            "affiliation": "Chung-Nam National University Hospital", 
            "last_name": "Jang-Hee Hong, M.D., Ph.D.", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Korea: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "April 2012", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "measure": "Cmax and AUCt of clopidogrel", 
                "safety_issue": "No", 
                "time_frame": "24hrs"
            }, 
            {
                "measure": "Cmax and AUCt of Acetylsalicylic acid", 
                "safety_issue": "No", 
                "time_frame": "24hrs"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01657071"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Tmax, T1/2, \u03bbz and AUC\u221e of Clopidogrel and Acetylsalicylic acid   - AUCt, Cmax, Tmax, T1/2, \u03bbz and AUC\u221e of salicylic acid", 
                "safety_issue": "No", 
                "time_frame": "24hrs"
            }, 
            {
                "measure": "AUCt, Cmax, Tmax, T1/2, \u03bbz and AUC\u221e of salicylic acid", 
                "safety_issue": "No", 
                "time_frame": "24hrs"
            }
        ], 
        "source": "Yuhan Corporation", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Yuhan Corporation", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "March 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "July 2012"
    }
}